This observational study with prospectively collected data examines a cohort of 3408 men and women with stage I to III colorectal cancer (CRC) to evaluate the association of body mass index at the time of and following CRC diagnosis with risk of mortality.
This cohort study examines the association between physical activity and digestive system cancer risk, accounting for amount, type (aerobic vs resistance), and intensity of physical activity.
This study analyzes data from 2 large US cohorts and the US white population to evaluate the association of lifestyle factors with cancer incidence and mortality.
This secondary analysis of a randomized clinical trial investigates whether molecular subtypes of colon cancer are associated with differential prognosis and benefit from oxaliplatin added to fluorouracil plus leucovorin therapy.
This multisite cohort study of 685 women younger than 70 years with nonmetastatic invasive breast cancer explores whether complementary and alternative medicine use is associated with decreased breast cancer chemotherapy initiation.
This subgroup analysis of a randomized clinical trial evaluates the safety and potential benefit of treatment with nivolumab, a programmed cell death 1 immune checkpoint inhibitor, beyond first progression of metastatic renal cell carcinoma.
This nationwide matched cohort study in a Swedish population and health registers examines the relative risks of several mental disorders during the periods before and after cancer diagnosis compared with individuals without cancer.
This prospective cohort analysis evaluates the association between intake of marine ω-3 polyunsaturated fatty acids and risk of colorectal cancer characterized by immune infiltrate.
This study uses data from the US National Cancer Data Base to examine the adoption of androgen deprivation therapy vs dose-escalated radiotherapy for prostate cancer across the United States.
This study assesses the number of cancer therapies approved by the US Food and Drug Administration that achieved the clinically meaningful improvements suggested by the American Society of Clinical Oncology.
This case series describes biopsy-proven treatment-induced resistance mutations acquired by patients with non–small-cell lung cancer and EGFR mutations treated with erlotinib.
This systematic review analyzes advanced pancreatic adenocarcinoma phase 3 clinical trials performed over the past 25 years.
This review summarizes available and candidate biomarkers for the selection of patients who might benefit from the use of PD-1/PD-L1 inhibitors for the treatment of non–small-cell lung cancer.
This Viewpoint examines the results of a survey of 19 tumor surgeons regarding their experiences with oncologic 3-D models; surgeons were asked how helpful the models were or how likely the models were to improve care.
This Viewpoint questions the necessity of frequent cardiovascular monitoring for patients receiving trastuzumab therapy and proposes that intense monitoring be reserved for patients with risk factors shown to be associated with congestive heart failure.
This Viewpoint uses Medicare's 2016 Proposed Part B Drug Payment Model to discuss alternative drug payment models that would align drug costs with value, keep drugs affordable while rewarding innovation, and incorporate patient values and preferences.
This commentary discusses a study published in JAMA that evaluated the effect of a combination of sulindac and erlotinib on duodenal adenoma regression in patients with familial adenomatous polyposis.
Create a personal account or sign in to: